Imdevimab is part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. Imdevimab is a monoclonal antibody combined with casirivimab in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19.
- Mechanism
- Curator reviewed · 4 references
Imdevimab is a recombinant human IgG1 monoclonal antibody targeting the receptor binding domain of the spike protein of SARS-CoV-2; a protein playing an important role in viral attachment, fusion, and entry into the target cell by binding to the ACE2 receptor. Together with casirivimab, imdevimab neutralizes the spike protein of SARS-CoV-2.
- Primary indication
- According to the Emergency Use Authorization (EUA) by the FDA and EMA, indevimab is used only with casirivimab to prevent COVID-19 and treat mild to moderate COVID-19 from laboratory-confirmed SARS-CoV-2 infection in patients aged 12...Curator reviewed · 2 structured indications
- First approval
- Canada, 2021 · European Union, 2021
- Code names
- REGN-10987
- Brand names
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with Imdevimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account